GlassScriptPhysician profile
Ryan Bolotte
NPI 1497318018
$4,039.50
in general payments reported to CMS, 2019-2025
21 companies · $2,584 in 2025
The $2,584 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $652 · 2024: $803 · 2025: $2,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,518 · Grant: $500 · Consulting Fee: $21.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.87 |
| Grant | $500.00 |
| Consulting Fee | $21.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $560.63 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $524.58 | 2024-2025 | Airsupra, Fasenra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $398.55 | 2024-2025 | Takhzyro, Cuvitru, Hyqvia |
| Grifols USA, LLC | $387.81 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $342.04 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $294.14 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $278.14 | 2025 | Neffy |
| Amgen INC. | $237.51 | 2024-2025 | Tezspire, Actimmune |
| Glaxosmithkline, LLC. | $188.54 | 2025 | Trelegy Ellipta, Nucala |
| Csl Behring | $144.34 | 2025 | Andembry, Hizentra, Haegarda |
| Genentech USA, INC. | $131.31 | 2024-2025 | Xolair |
| Pfizer INC. | $111.20 | 2025 | |
| Incyte Corporation | $83.60 | 2025 | Opzelura |
| Biocryst US Sales Co., LLC | $81.45 | 2024-2025 | Orladeyo |
| Alk-Abello, INC | $65.65 | 2025 | Odactra, Ragwitek, Grastek |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.94 | 2024-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $39.14 | 2025 | Zoryve |
| Kaleo, INC. | $32.84 | 2024 | Auvi-Q |
| Ionis Pharmaceuticals, INC. | $30.43 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $28.03 | 2025 | Ruconest |
| Adma Biomanufacturing LLC | $21.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bolotte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.